Medium
WHAT are your options?
- Nirsevimab (monoclonal antibody - passive immunization)
- AstraZeneca
- Sanofi
WHO is eligible?
Child's 1st RSV season: All infants 8 months and younger
Child's 2nd RSV season: High-risk infants 8-19 months, including American Indian
HOW well do they work?
Reduces risk of hospitalization and health care visits by 80%
WHEN should I get it?
Will be available soon. Protection lasts 4-6 months.